Sequence: stearyl-HEHHEHHEHEHGFLGRVRVLRGDKW-amide
| Experiment Id | EXP000541 |
|---|---|
| Paper | A novel multitargeted self-assembling peptide-siRNA complex for simultaneous inhibition of SARS-CoV- |
| Peptide | HE25 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | 25–50 nM (in vitro functional assays) |
| Mixing Ratio | 1:20–1:100 (siRNA:peptide molar ratios) |
| Formulation Format | Self-assembling peptide–siRNA complex |
| Formulation Components | HE25 peptide noncovalently complexed with siRNA via electrostatic and hydrophobic interactions |
| Size Nm | 100.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Vero E6; NCI-H358 lung epithelial cells |
| Animal Model | |
| Administration Route | |
| Output Type | Gene silencing (RT-qPCR, GAPDH assay); viral replication inhibition (plaque assay); uptake (confocal) |
| Output Value | Up to ~85% GAPDH knockdown; up to 90–100% inhibition of SARS-CoV-2 replication in vitro |
| Output Units | |
| Output Notes | Functional delivery depends on optimal molar ratios (1:20–1:80). Both entry blockade and siRNA silencing contribute. |
| Toxicity Notes | No cytotoxicity reported in vitro at effective doses |
| Curation Notes |